Insider Trading disclosures for Atyr Pharma Inc

The latest disclosure was made by Jane A. Gross in Atyr Pharma Inc where a trade of 3,750 Common Stock done at an average price of $4 was reported to US exchanges on March 17, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Jane A. Gross	Director	Purchase of securities on an exchange or from another person at price $ 4.00 per share.	17 Mar 2025	3,750	9,750 (0%)	0%	4	15,000	Common Stock
Jill M. Broadfoot	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	03 Feb 2025	3,750	33,017 (0%)	0%		-	Common Stock
Jill M. Broadfoot	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 3.78 per share.	03 Feb 2025	1,254	31,763 (0%)	0%	3.8	4,740	Common Stock
Jill M. Broadfoot	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	03 Feb 2025	3,750	3,750	-		-	Restricted Stock Unit
Nancy E. Denyes	General Counsel	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	03 Feb 2025	2,687	2,687	-		-	Restricted Stock Unit
Nancy E. Denyes	General Counsel	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	03 Feb 2025	2,687	27,454 (0%)	0%		-	Common Stock
Nancy E. Denyes	General Counsel	Sale of securities on an exchange or to another person at price $ 3.78 per share.	03 Feb 2025	899	26,555 (0%)	0%	3.8	3,398	Common Stock
Sanjay S. Shukla	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	03 Feb 2025	10,375	10,375	-		-	Restricted Stock Unit
Sanjay S. Shukla	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	03 Feb 2025	10,375	146,923 (1%)	0%		-	Common Stock
Benevich S. Eric	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	10 Dec 2024	100,000	100,000	-		-	Stock Option (right to buy)
Paul R. Schimmel	Director	Purchase of securities on an exchange or from another person at price $ 1.93 per share.	22 Jul 2024	52,300	413,023 (4%)	0%	1.9	101,038	Common Stock
Paul R. Schimmel	Director	Purchase of securities on an exchange or from another person at price $ 1.82 per share.	22 Jul 2024	6,648	360,723 (4%)	0%	1.8	12,075	Common Stock
Paul R. Schimmel	Director	Purchase of securities on an exchange or from another person at price $ 1.74 per share.	22 Jul 2024	41,052	354,075 (4%)	0%	1.7	71,500	Common Stock
Nancy E. Denyes	General Counsel	Purchase of securities on an exchange or from another person at price $ 1.86 per share.	05 Jun 2024	5,000	22,267 (0%)	0%	1.9	9,276	Common Stock
Jill M. Broadfoot	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 1.79 per share.	31 May 2024	5,000	27,960 (0%)	0%	1.8	8,950	Common Stock
Sanjay S. Shukla	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 1.81 per share.	31 May 2024	20,000	136,548 (1%)	0%	1.8	36,140	Common Stock
Timothy P. Coughlin	Director	Purchase of securities on an exchange or from another person at price $ 1.75 per share.	30 May 2024	50,000	56,000 (0%)	0%	1.8	87,500	Common Stock
Paul R. Schimmel	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 May 2024	24,000	24,000	-		-	Stock Option (right to buy)
John K. Clarke	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 May 2024	24,000	24,000	-		-	Stock Option (right to buy)
Timothy P. Coughlin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 May 2024	24,000	24,000	-		-	Stock Option (right to buy)
Sara Zaknoen	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 May 2024	24,000	24,000	-		-	Stock Option (right to buy)
Jane A. Gross	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 May 2024	24,000	24,000	-		-	Stock Option (right to buy)
Svetlana Lucas	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 May 2024	24,000	24,000	-		-	Stock Option (right to buy)
Shukla Sanjay S.	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Feb 2024	10,375	116,548 (1%)	0%		-	Common stock
Shukla S. Sanjay	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Feb 2024	10,375	20,750	-		-	Restricted Stock Unit
Broadfoot M. Jill	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 1.69 per share.	05 Feb 2024	1,590	20,821 (0%)	0%	1.7	2,687	Common stock
E. Nancy Denyes	General Counsel	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Feb 2024	2,688	5,374	-		-	Restricted Stock Unit
E. Nancy Denyes	General Counsel	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Feb 2024	2,688	14,767 (0%)	0%		-	Common stock
Jill M. Broadfoot	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Feb 2024	3,750	7,500	-		-	Restricted Stock Unit
Jill Broadfoot M.	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Feb 2024	3,750	22,411 (0%)	0%		-	Common stock
M. Jill Broadfoot	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Jan 2024	150,000	150,000	-		-	Employee Stock Option (right to buy)
E. Denyes Nancy	General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Jan 2024	150,000	150,000	-		-	Employee Stock Option (right to buy)
Sanjay Shukla S.	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Jan 2024	600,000	600,000	-		-	Employee Stock Option (right to buy)
Sanjay Shukla S.	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 1.17 per share.	11 Dec 2023	3,000	94,173 (1%)	0%	1.2	3,510	Common Stock
Sanjay Shukla S.	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 1.18 per share.	11 Dec 2023	12,000	106,173 (1%)	0%	1.2	14,136	Common Stock
Sanjay Shukla S.	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 1.14 per share.	10 Nov 2023	1,422	77,595 (0%)	0%	1.1	1,618	Common Stock
S. Shukla Sanjay	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 1.11 per share.	10 Nov 2023	13,578	91,173 (1%)	0%	1.1	15,085	Common Stock
Sanjay S. Shukla	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 2.01 per share.	28 Jul 2023	15,000	76,173 (0%)	0%	2.0	30,224	Common Stock
Paul R. Schimmel	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 May 2023	12,000	12,000	-		-	Stock Option (right to buy)
John K. Clarke	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 May 2023	12,000	12,000	-		-	Stock Option (right to buy)
Timothy P. Coughlin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 May 2023	12,000	12,000	-		-	Stock Option (right to buy)
Timothy P. Coughlin	Director	Gift of securities by or to the insider at price $ 0.00 per share.	17 May 2023	6,000	6,000 (0%)	0%		0	Common Stock
Timothy P. Coughlin	Director	Gift of securities by or to the insider at price $ 0.00 per share.	17 May 2023	6,000	0 (0%)	0%		0	Common Stock
Sara Zaknoen	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 May 2023	12,000	12,000	-		-	Stock Option (right to buy)
Jane A. Gross	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 May 2023	12,000	12,000	-		-	Stock Option (right to buy)
Svetlana Lucas	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 May 2023	12,000	12,000	-		-	Stock Option (right to buy)
Paul R. Schimmel	Director	Purchase of securities on an exchange or from another person at price $ 2.25 per share.	10 May 2023	200,000	313,023 (3%)	2%	2.3	450,000	Common Stock
Paul R. Schimmel	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	26 Apr 2023	6,000	8,890 (0%)	0%		-	Common stock
Paul R. Schimmel	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	26 Apr 2023	6,000	0	-		-	Restricted Stock Unit
John K. Clarke	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	26 Apr 2023	6,000	0	-		-	Restricted Stock Unit

Showing 1 to 50 of 407 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

29.83% Fall from 52W High

Insider Trading disclosures for Atyr Pharma Inc

The latest disclosure was made by Jane A. Gross in Atyr Pharma Inc where a trade of 3,750 Common Stock done at an average price of $4 was reported to US exchanges on March 17, 2025.

Screeners based on Insider Trading and SAST parameters